About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Ohio | 17,983 Studies Near You | Clareo Health

Clinical Trials LocationsOhio

Clinical Trials in Ohio

Discover 17,983 clinical trials near Ohio. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 2821-2840 of 17,983 trials

Enrolling By InvitationPhase 2/332 miles

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

NCT05883748

This is an open-label, long-term extension study to investigate the safety, tolerability and efficacy of DISC-1459 in participants with EPP.

Erythropoietic Protoporphyria

Disc Medicine, Inc230 participantsStarted Aug 2023

Birmingham, Alabama, United States • San Francisco, California, United States • Miami, Florida, United States +10 more locations

RECRUITING32 miles

Blue Light Cystoscopy With Cysview® Registry

NCT02660645

Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

Photocure4,400 participantsStarted Apr 2014

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Los Angeles, California, United States +20 more locations

Find Trials by Condition in Ohio

Breast Cancerin Ohio Lung Cancerin Ohio Prostate Cancerin Ohio Colorectal Cancerin Ohio Melanomain Ohio Leukemiain Ohio Lymphomain Ohio Pancreatic Cancerin Ohio Ovarian Cancerin Ohio Brain Cancerin Ohio Diabetesin Ohio

Data from ClinicalTrials.govTerms

Active Not RecruitingNA32 miles

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

NCT03656835

This trial studies how well nanochip technology (immuno-tethered lipoplex nanoparticle \[ILN\] biochip) works in monitoring treatment response and in detecting relapse in participants with diffuse large B-cell lymphoma. Finding genetic markers for diffuse large B-cell lymphoma may help identify participants with this disease and help predict the outcome of treatment. It is not yet known how well ILN biochip-based testing monitors treatment response or detects relapse in participants with diffuse large B-cell lymphoma.

Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+1 more

Ohio State University Comprehensive Cancer Center73 participantsStarted Sep 2018

Columbus, Ohio, United States

TERMINATEDPhase 1/295 miles

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

NCT05860296

SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the study site staff on the first day of every cycle. This study has 2 parts. The first part will determine the recommended dose of SLC-391 in combination with pembrolizumab. The second part wants to find out if the combination of SLC-391 and pembrolizumab can help stop NSCLC tumours from growing or spreading.

Lung Cancer, Nonsmall CellLung Cancer Stage IVLung Cancer Metastatic

SignalChem Lifesciences Corporation36 participantsStarted May 2023

Indianapolis, Indiana, United States • Lafayette, Indiana, United States • Detroit, Michigan, United States +9 more locations

Active Not RecruitingNA95 miles

SyncAV Post-Market Trial

NCT04100148

The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices programmed with conventional CRT through evaluation of changes in left ventricular (LV) reverse remodeling.

Congestive Heart Failure

Abbott Medical Devices1,686 participantsStarted Oct 2019

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Scottsdale, Arizona, United States +101 more locations

Active Not RecruitingPhase 3109 miles

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

NCT03950232

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 \[NCT03945188\] or APD334-302 \[NCT03996369\] or APD334-210 \[NCT04607837\]).

Ulcerative Colitis

Pfizer896 participantsStarted Sep 2019

Dothan, Alabama, United States • Dothan, Alabama, United States • Dothan, Alabama, United States +466 more locations

Active Not RecruitingPhase 3127 miles

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

NCT06634420

This Phase 3 study aims to evaluate the efficacy and safety of NTLA-2002 compared to placebo in participants with HAE.

Hereditary Angioedema

Intellia Therapeutics60 participantsStarted Jan 2025

Scottsdale, Arizona, United States • San Diego, California, United States • Santa Monica, California, United States +26 more locations

TERMINATEDPhase 1127 miles

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

NCT05336409

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participants with relapsed or refractory cluster of differentiation (CD)19-positive B-cell malignancies.

R/R CD19-Positive B-Cell MalignanciesIndolent Non-Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma

Century Therapeutics, Inc.28 participantsStarted Jan 2023

Gilbert, Arizona, United States • Los Angeles, California, United States • San Diego, California, United States +13 more locations

COMPLETEDPhase 2196 miles

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

NCT06001177

The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)

Celiac DiseaseCoeliac Disease

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA55 participantsStarted Dec 2023

Colorado Springs, Colorado, United States • Hialeah Gardens, Florida, United States • Miami, Florida, United States +25 more locations

Active Not RecruitingPhase 1/2287 miles

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

NCT03069469

This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.

Advanced Malignant NeoplasmPigmented Villonodular SynovitisGiant Cell Tumor of Tendon Sheath+2 more

Deciphera Pharmaceuticals, LLC120 participantsStarted Feb 2017

Palo Alto, California, United States • Denver, Colorado, United States • Jacksonville, Florida, United States +21 more locations

RECRUITINGNA316 miles

CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms

NCT05663034

This study is a prospective two-arm, single blind randomized controlled trial design to compare the clinical effectiveness of telemedicine-delivered, 6-session, standardized cognitive behavioral therapy for insomnia (CBT-I) and mindfulness-based treatment for insomnia (MBTI) in treating insomnia symptoms and ameliorating depressive symptoms in persons with mild to moderate TBI and comorbid Post-Traumatic Stress Symptoms (PTSS) and insomnia symptoms in a 360 patients. Participants will undergo assessment (psychosocial questionnaires, neurocognitive testing, sleep monitoring) at baseline, at the end of treatment, and at 2-, 6- and 12-weeks post-treatment. The primary outcome is sleep as measured by the Insomnia Severity Index (ISI).

Traumatic Brain InjuryInsomniaDepression+7 more

Johns Hopkins University360 participantsStarted May 2024

Eglin Air Force Base, Florida, United States • Eglin Air Force Base, Florida, United States • Bethesda, Maryland, United States +2 more locations

Enrolling By Invitation325 miles

The Johns Hopkins Heartburn Center Registry

NCT03853772

A multi-center, multi-year registry of patients with gastroesophageal reflux disease (GERD) undergoing diagnostic evaluation and/or treatment of GERD and associated diseases and complications.

Gastroesophageal Reflux DiseaseBarrett EsophagusLaryngopharyngeal Reflux+1 more

Johns Hopkins University2,000 participantsStarted Apr 2019

Orange, California, United States • Baltimore, Maryland, United States • Rochester, Minnesota, United States +6 more locations

COMPLETEDNA360 miles

Multisite Virtual Reality Intervention for Speech Anxiety

NCT06593847

Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present multicenter study (conducted through the Exposure Therapy Consortium) is designed to evaluate whether trait versus state positive affectivity is a more effective predictor of exposure therapy outcomes. Further, the investigators will examine whether the predictive significance of trait positive affectivity can be accounted for by examination of baseline levels of self-efficacy, hope, and optimism.

Public SpeakingSpeech Anxiety

Boston University Charles River Campus1,542 participantsStarted Oct 2024

Tucson, Arizona, United States • Carbondale, Illinois, United States • Boston, Massachusetts, United States +10 more locations

TERMINATEDPhase 1364 miles

M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

NCT06509906

The purpose of this study is to evaluate the safety and preliminary clinical activity of M9466 in combination with topoisomerase 1 inhibitors-based regimens. As such the combination with FOLFIRI (folinic acid, fluorouracil, irinotecan) and Bevacizumab will be evaluated in participants with colorectal cancer, to establish the M9466 maximum tolerated dose if observed and the recommended dose for expansion. Study Duration: After a Screening period of up to 28 days, enrolled participants will remain in the study until they have completed all the study visits or until they withdraw consent, are lost to follow-up, or die. Visit Frequency: The participants will come for a Screening Visit and 1 to 2 visits per treatment cycle. After end of study intervention period, the participants will come for an End of Treatment Visit and a Safety Follow-up Visit.

Advanced Solid Tumor

EMD Serono Research & Development Institute, Inc.3 participantsStarted Oct 2024

Denver, Colorado, United States • Pennington, New Jersey, United States • Nashville, Tennessee, United States +9 more locations

Active Not RecruitingNA364 miles

MoVE Trial: Motivational Strategies to Empower African Americans to Improve Dialysis Adherence

NCT05735743

MoVE Trial is a randomized clinical trial designed to rigorously test the impact of a behavioral intervention (culturally tailored motivational interviewing - (MOVE)) delivered by trained health coaches, on hemodialysis treatment non-adherence. It is a a two-arm, parallel group randomized clinical trial with 24-week follow-up. It involves completion of surveys by patients enrolled in the study. It also involves participation in motivational interviewing sessions by patients who are randomized to the intervention (MI).

End Stage Renal Disease on Dialysis

Vanderbilt University Medical Center176 participantsStarted Oct 2023

Philadelphia, Pennsylvania, United States • Philadelphia, Pennsylvania, United States • Philadelphia, PA 19123, Pennsylvania, United States +3 more locations

Active Not RecruitingNA518 miles

Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations

NCT05286879

This is a 5-year Hybrid Type 1 Effectiveness-Implementation Randomized Control Trial (RCT) that compares two models of linking and retaining individuals recently released from justice involvement to the continuum of community-based HIV prevention and treatment, HCV treatment, STI treatment, and opioid use disorder (OUD) prevention and treatment, medication for opioid use disorder (MOUD) service cascades of care.

Opioid Use DisorderInfectious DiseaseRisk Reduction Behavior+3 more

Yale University600 participantsStarted Mar 2022

New Haven, Connecticut, United States • Dallas, Texas, United States • Fort Worth, Texas, United States

Active Not RecruitingPhase 2556 miles

Study of Aspirin in Patients With Vestibular Schwannoma

NCT03079999

This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.

Vestibular SchwannomaAcoustic NeuromaNeurofibromatosis 2

Massachusetts Eye and Ear Infirmary97 participantsStarted Jun 2018

Stanford, California, United States • Miami, Florida, United States • Boston, Massachusetts, United States +2 more locations

COMPLETEDPhase 3651 miles

A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement

NCT05603832

This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14 (625 mg sustained release celecoxib) administered concurrent with multimodal analgesia in patients undergoing total knee replacement surgery, compared to multimodal analgesia alone.

Post Operative Pain

Arthritis Innovation Corporation151 participantsStarted Nov 2022

Little Rock, Arkansas, United States • Tamarac, Florida, United States • Tulsa, Oklahoma, United States +4 more locations

Enrolling By Invitation1987 miles

An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

NCT04049084

This observational long-term follow-up study is designed to collect safety and efficacy data from ADA-SCID patients previously treated with autologous ex vivo gene therapy products based on the EFS-ADA LV encoding for human adenosine deaminase (ADA) gene (EFS-ADA LV), as part of the OTL-101 clinical development program. No investigational medicinal product will be administered to these patients as part of the OTL-101-6 study.

Adenosine Deaminase DeficiencySevere Combined Immunodeficiency (SCID)

University of California, Los Angeles70 participantsStarted Sep 2019

Los Angeles, California, United States • London, United Kingdom

Active Not Recruiting1987 miles

Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)

NCT06282432

This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safety and efficacy of the infusion of autologous hematopoietic stem cells transduced with a lentiviral vector encoding the ITGB2 gene

Leukocyte Adhesion Deficiency

Rocket Pharmaceuticals Inc.9 participantsStarted Mar 2022

Los Angeles, California, United States • Madrid, Spain • London, United Kingdom

PreviousPage 142 of 900Next

Heart Diseasein Ohio